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Background: Tobacco smoking remains the leading cause of preventable death in America, claiming 450,000 lives
annually. Chronic Obstructive Pulmonary Disease, caused by smoking in the vast majority of cases, became the
third leading cause of death in the U.S. in 2008. The burden of asthma, often exacerbated by tobacco exposure, has
widespread clinical and public health impact. Despite this considerable harm, we know relatively little about the
natural history of lung disease and respiratory impairment in adults, especially after smoking cessation.
Methods/Design: Our paper describes the design and rationale for using the 2004 Federal Bureau of Prisons
tobacco ban to obtain insights into the natural history of respiratory diseases in adult men and women of
different races/ethnicities who are imprisoned in federal medical facilities. We have developed a longitudinal
study of new prison arrivals, with data to be collected from each participant over the course of several years,
through the use of standardized questionnaires, medical chart reviews, lung function tests, six-minute walk tests,
and stored serum for the analysis of present and future biomarkers. Our endpoints include illness exacerbations,
medication and health services utilization, lung function, serum biomarkers, and participants’ experience with
their health and nicotine addiction.
Discussion: We believe the proposed longitudinal study will make a substantial contribution to the
understanding and treatment of respiratory disease and tobacco addiction.
Keywords: Pulmonary disease, Chronic Obstructive Pulmonary Disease, Asthma, Pathophysiology, Biomarkers,
Pulmonary function tests, Tobacco, Nicotine, Addiction, Health servicesBackground
Tobacco smoking remains the leading cause of prevent-
able death in America and is viewed as “the No. 1 public
health concern in the nation and the world” [1-3].
Tobacco’s impact on coronary heart disease and cancer
is rivaled only by its role in Chronic Obstructive Pul-
monary Disease (COPD), the third leading cause of
death in America; smoking cessation and supplemental
oxygen remain the only means to reduce mortality for
this disease [4]. In 2008, COPD directly accounted for
822,500 hospitalizations among American men and
women and was listed as a contributory cause in an add-
itional 3.8 million hospitalizations [5]. In addition to the* Correspondence: stephen.martin@umassmemorial.org
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reproduction in any medium, provided the ordirect effects of smoking on these illnesses, there is a
significant population of patients with asthma and other
illnesses who are adversely affected by second-hand
smoke [6-8].
Our understanding of the pathophysiology of COPD
preceded large-scale tobacco policies, remaining largely
informed by the 1960’s study of British industrial work-
ers [9,10]. This prospective study generated the first
comprehensive insights into the clinical epidemiology of
COPD and established FEV1 as the gold standard diag-
nostic test [11]. Data showing that participants who quit
smoking could normalize their rate of lung function de-
cline, but not reverse existing pulmonary damage, was
one of this study’s most important findings. This conclu-
sion, however, had significant caveats as findings were
based on a relatively small study sample and on self-
reported smoking data. In 1976, these and other limita-
tions led the authors to note that “Further studies areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ume] that occur in obstructed smokers when they stop
smoking . . ..” [12,13].
Despite this need for further research, there have been
very few long-term cohort studies of smoking cessation
and assessment of its effects on lung health and other
disease parameters [14-16]. More recent observational
studies have enrolled large numbers of participants and
collected comprehensive clinical information [17,18].
Despite the size and breadth of these investigations,
early results of these studies highlight our present limita-
tions in understanding lung disease, and question our
understanding of its pathogenesis and diagnosis [19].
For example, data published in 2011 from the ECLIPSE
study found that in 2,163 COPD subjects, 15% had ac-
tual improvement in their lung function due to unknown
contributory factors [20].
While the costs, constraints, and challenges of long-
term observational studies and interventional trials are a
serious impediment to understanding the progression of
chronic diseases, a natural experiment is currently
underway in U.S. prisons. As of 2008, more than half of
U.S. states as well as the Federal Bureau of Prisons
(BOP) had a total tobacco ban; the BOP ban began in
2004 [21]. Several studies have begun to delineate the
impact of these bans. The existing literature, however,
has generally focused on characterizing smokers’ addic-
tion and behavior in partial ban settings or over limited
periods of time. [22-25]. Our proposed longitudinal
study will be able to address a number of important
unanswered questions in the field through the use
of a study population with and without medical co-
morbidities, under a verifiable complete smoking ban
over an extended period of follow-up. The present inves-
tigation will, for the first time, allow a comprehensive
and systematic assessment of the effects of enforced
smoking abstinence on respiratory symptoms, pulmon-
ary physiology, biomarkers, and outcomes known to
relate to an individual’s long-term survival and health-
related quality of life. Though conducted in a prison set-
ting, the subjective, clinical, pulmonary function, and
biomarker results would apply to the general population.
We hypothesize our natural history study will find dis-
tinct subgroup patterns of improvement, plateau, or
decline in terms of health service utilization, lung im-
pairment, and biomarkers. We see this variability as a
contrast to the traditional course as interpreted from
Fletcher and Peto’s data and more consistent with the
ECLIPSE study cited above and recent findings in bio-
marker patterns [26-29]. If found, such subgroups may
allow for the development of targeted therapeutic care.
In addition to information on pulmonary health, the
study also allows for considerable impact on public
health. With 1% of the U.S. population being incarceratedin a given year, and more than 12% of U.S. smokers
released annually from incarceration, exploring a durable
means of tobacco abstinence post-release could have a
powerful health effect beyond prison [30]. Several studies
have shown substantial cardiovascular mortality asso-
ciated with release from prison; this risk may be due to
the high prevalence of tobacco use in the corrections
population [31]. Our protocol will allow for a deeper
understanding of nicotine addiction in the setting of
long-term enforced abstinence and provide for future
informed interventions prior to release. Understanding
tobacco addiction during and after prison may also help




This prospective epidemiologic study will enroll new
inmates at Federal Medical Center (FMC) Devens
(Devens, MA) and FMC Carswell (Fort Worth, TX)
and follow all consenting participants over a five-year
period. Devens houses only male inmates and Carswell
is the only federal prison medical center for women.
FMCs care for the sickest federal inmates; 25% or more
of the population at these two facilities are designated
as having a high medical need. Other than a dispropor-
tionally older population, FMCs have similar demo-
graphics to other prisons in their region and are each
approximately the same size.
The overall BOP population (N = 216,511) is 38%
Black and 59% White, with 35% reporting Hispanic
ethnicity. The vast majority of inmates are male (94%)
and the average age of this population is 39 years [32].
FMC Devens and FMC Carswell represent populations
with considerable race and ethnicity diversity and mi-
rror the general BOP population. While this study
represents a poorer, less educated, more minority
population than the U.S. as a whole, it does represent
the population most impacted by tobacco-related dis-
ease [33].
Participant recruitment
Participants will meet pre-defined inclusion criteria,
including:
1) Arriving as a self-surrender (coming from home
setting to begin a federal sentence) or as a transfer
from a county, state, or other federal prison. In the
case of non-federal transfers, note will be made of
the tobacco policy of the transferring institution as
well as the amount of time the participant was under
a tobacco ban;
2) Are anticipated to be in a Bureau prison for at least
one year after the initial study start date;
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total pack-years and having smoked within the past
two years; and
4) Are able to understand and consent to the study
procedures.
Once deemed eligible, each inmate will be asked to pro-
vide informed consent and will be enrolled into the study.
The study is explained in detail to potential participants,
questions answered, they are informed of their rights to
quit at any time, and also informed that participation will
not influence any prison privileges, probation or parole. If
the individual is still interested in participating then the
consent form is signed by the inmate. All incentives for
participation are prohibited by the BOP. This study is
approved by the University of Massachusetts Medical
School Institutional Review Board and the Federal Bureau
of Prisons Research Review Board.
Sample size considerations
Sample size was selected to permit analysis of the pri-
mary dependent variable, FEV1, at an alpha of 0.05
one-tailed and a power level of at least 0.80. A recent sys-
tematic review of 47 studies found an expected FEV1 de-
cline of 28 mL/year in non-smokers and 33 mL/year in
smokers who quit after baseline; a recent observational
study of subjects with COPD also found a decline of
33 mL/year over three years [20,34]. Our sample size re-
quirement of approximately 250 participants will be able
to detect an average improvement in FEV1 of 10 mL/year.
Data collection activities
Participants in this study will complete a detailed base-
line questionnaire including participants’ demographic
characteristics, lifestyle practices, and smoking history.
Standardized and validated measures will also be obtained
at intake including: the COPD Assessment Test (CAT),
Modified Medical Research Council Dyspnea Scale, the
Charlson Self-Report, the Healthy Days Core Module
(CDC HRQOL-4), the Autonomy over Smoking Scale
(AUTOS), the Hooked on Nicotine Checklist (HONC), the
Hughes/Hatsukami Withdrawal Scale, the Questionnaire
of Smoking Urges – Brief (QSU-Brief), and the Center for
Epidemiologic Studies Depression Scale (CES-D). The four
smoking questionnaires will allow comparisons with exist-
ing studies. The initial set of questionnaires takes partici-
pants less than 1 hour to complete. In the follow-up
assessment, designed to take fifteen minutes, only the
AUTOS and QSU-Brief questionnaires are administered.
Using the standardized survey questionnaires and informa-
tion obtained from the review of the medical chart, we will
longitudinally examine an inmate’s perceived quality of life,
reported symptoms, medical diagnoses, medication usage,
quantity/cause of prison clinic visits, COPD/asthmaexacerbations, quantity/duration of any hospitalizations,
and other important related factors.
Study participants’ clinical characteristics will be
assessed by conducting a six-minute walk test (6MWT),
pre-/post-bronchodilator spirometry, and the diffusion
capacity of the lung for carbon monoxide (DLCO)
according to American Thoracic Society standards. We
will also calculate a BODE index from the body-mass
index (B), degree of airflow obstruction (O), dyspnea
(D), and exercise capacity (E), measured by the six-
minute walk test. This index is a prospectively verified
predictor of COPD related mortality [35]. A hand
squeeze test will also be administered to measure per-
ipheral muscle strength. Blood and urine samples will be
obtained to assess CBC with differential, and levels of C-
reactive protein, urine microalbumin, BUN/Cr/GFR, and
Hgb A1c; these biomarkers have been associated with
tobacco consumption and with the development of car-
diovascular and respiratory disease. Additional blood will
be stored and tested for the presence of nine biomarkers
(MMP9, VEGF, IL-1β, IL-6, PARC [CCL18], LTB4,
ADAM8, ACE, and CC16) [36]. In a separate process,
we will seek informed consent to allow a frozen blood
sample to be stored under standard cryogenic conditions
for future studies related to tobacco and disease [37]. All
personal identifiers will be removed from stored
samples.
At defined intervals (initial, 1, 3, and 6 months, 1 year
and annually for 5 years total) we will re-administer
questionnaires, clinical, respiratory, and serum tests to
collect ongoing data on the inmates’ current health sta-
tus as noted above.
Time plan
The development of this study began in July of 2009.
IRB approval was granted in 2010 and, after further
planning, initial enrollment began in March 2011.
Planned analysis
All collected data will be summarized and presented
with the use of simple descriptive statistics using chi
square tests to examine differences in various categorical
variables (e.g., presence of co-morbid conditions) and
t tests to examine differences in selected continuous
variables (e.g., physiologic variables) between various
comparison groups. Participants will be stratified by how
recently they have smoked in our analyses as well as
according to the number of cigarettes they smoked and
duration of their smoking habit. Longitudinal data ana-
lyses will be conducted, including the use of life table
methods and person-time approaches, and generalized
linear models will be developed using backward stepwise
regression methods to identify factors associated with
various health related outcomes. We will also utilize
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time-dependent findings.
Discussion
Pivotal clinical and public health research often takes
advantage of unusual circumstances. There has been a
growing call for work on the natural history of lung
disease and biomarkers and our study offers a high-yield
approach [13,14]. Prisons offer a rare opportunity to
study a smoke-free community and its impact on human
health and illness. Prisons also have populations with
significant co-morbidities and health disparities who are
important to study [38,39].
This comprehensive assessment, all in the setting of a
prison tobacco ban, will provide unique insights into the
natural history of respiratory disease in the absence of
tobacco. With the storage of biological samples at vari-
ous lengths of time of tobacco abstinence, we will also
be able to examine the effects of smoking cessation on
markers of cell injury and repair and potentially identify
therapeutic targets for tobacco-related disease. The col-
laboration with correctional health could also allow for
future intervention studies to decrease smoking post-
release, with substantial public health benefit [40]. Our
study will open important doors for research in tobacco-
related pathophysiology, biomarkers, addiction, correc-
tional and public health, health-related quality of life,
and health services utilization.
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